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Abstract 
 
Objectives 
To assess the feasibility of subclavian transcatheter aortic valve implantation (TAVI) using the Lotus 
valve.  
 
Background 
TAVI is used to treat patients with severe aortic stenosis, with trans-femoral (TF) access being the 
safest and most widely used route.  In the significant minority of patients unsuitable for this, there 
are reports that the subclavian artery may be safest alternative access route.  The Lotus device is a 
fully retrievable 2nd generation transcatheter heart valve which is licensed for femoral and trans-
aortic access.  There are limited data on the suitability of this valve for subclavian access. 
 
Methods 
We assessed the feasibility of trans-subclavian TAVI with the Lotus valve in patients unsuitable for TF 
TAVI.  Between January and October 2016, we identified 10 patients who underwent trans-
subclavian TAVI with the Lotus valve.  This cohort was compared with 347 (85%) patients who 
underwent trans-femoral TAVI, 45 (11%) patients who underwent and trans-apical or direct-aortic 
TAVI and the total group of 16 (4%) patients who underwent subclavian TAVI. 
 
Results 
10 patients aged 75 years (69-83) underwent attempted TAVI with the Lotus via subclavian access. 
Procedural success was 100%. In-hospital and 30-day mortality was zero. There were no nerological 
eventss, no vascular complications and no myocardial infarctions.  4 of 10 patients required a 
pacemaker post TAVI. No patient was left with moderate or greater aortic regurgitation. Median 
length of stay was 3 days post-procedure. 
 
Conclusions 
TAVI with the Lotus valve is feasible via the subclavian artery and appears safe with excellent 
outcomes in our patients.. 
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Introduction 
Aortic stenosis is the most common form of valvular heart disease in Europe and North America 
1,2
.  
Transcatheter aortic valve implantation (TAVI) reduces mortality compared with  medical therapy in 
patients deemed to be high risk with surgical aortic valve replacement (SAVR)
3
.  In patients with high 
or intermediate surgical risk, TAVI achieves similar survival at 1 year to SAVR
4,5
 and is  recommended 
by both American and European guidelines in patients with high surgical risk
6,7
. 
 
TAVI is most commonly performed via the femoral artery 
8,9
.   Trans-femoral access is associated 
with lower rates of mortality when compared to other routes
10,11
 which has led most operators to 
adopt a  “trans-femoral first” access strategy.  TAVI requires relatively large sheaths (minimum 14-
Fr) and delivery catheters and the transfemoral approach may not be feasible in patients with 
unsuitable vasculature. The trans-aortic and trans-apical are the most commonly used alternative 
access routes but have disadvantages including the greater invasiveness of a surgical thoracotomy
12
.  
The trans-subclavian approach to TAVI was initially described using the CoreValve (Medtronic, USA)
13
 
and subsequently using the Sapien valve (Edwards, USA)
14
.  Evidence is emerging that the trans-
subclavian route is safe
15
.  Observational  data have demonstrated that  survival following subclavian 
access is not significantly different from survival following TF access while survival following trans-
aortic/trans-apical access was significantly lower than trans-femoral and subclavian access
16,17
. 
 
The Lotus System (Boston Scientific, USA) is a 2
nd
 generation trans catheter heart valve approved for 
use in Europe in October 2013 and currently under evaluation in the USA.  It is fully repositionable 
and retrievable, designed to facilitate precise delivery
18
and has excellent results at 1 year, 
particularly in minimising para-valvular aortic regurgitation
19
.  This is particularly important as 
moderate or greater para-valvular regurgitation is associated with increased mortality following 
TAVI
5,20
.  Initially implanted via the femoral route, the valve is now licensed for trans-aortic access 
also.  The Lotus valve is currently not licensed in Europe for trans-subclavian access although there is 
is one report of the Lotus valve being delivered successfully via the subclavian artery
21
. 
 
Methods 
Between December 2008 and October 2016, our institution (Queen Elizabeth Hospital Birmingham, 
UK) performed 408 TAVI procedures.  Demographic, procedural and outcome data were entered 
prospectively to the National Institute for Cardiovascular Outcomes Research database.  The 
preferred access site was the femoral artery and this was used in 347 (85%) patients. Forty-six (11%) 
patients underwent trans-aortic/tran-apical access and 16 (4%) underwent trans-subclavian access 
of whom 10 underwent attempted TAVI with the Lotus Valve (Boston Scientific, USA).  Valve types 
implanted were Edwards Sapien (Irvine, CA, USA), 24 (5.8%); Edwards Sapien XT, 131 (32.1%); 
Edwards Sapien 3, 213 (52.2%), Lotus valve, 33 (8%); CoreValve (Medtronic, USA) 3 (0.7%); Evolute R 
(Medtronic, USA) 3 (0.7%). Between January and October 2016, 10 patients who were unsuitable for 
transfemoral TAVI underwent the procedure using the Lotus valve via the left subclavian artery.  
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All patients underwent a gated cardiac muti detector CT (MDCT)and helical MDCT of the aorta and 
ilio-femoral vessels. All patients were assessed by the Heart Team as being unsuitable for open heart 
surgery.  
Lotus Valve 
The Lotus valve consists a woven, nitinol wire, self-expanding frame to which is mounted a bovine 
pericardial aortic valve and is designed for catheter based introduction. The valve is expanded via 
controlled mechanical expansion. Rapid pacing is not required during valve deployment; the valve 
functions early in the deployment cycle and can be repositioned or fully retrieved at any point 
before uncoupling and valve release. An outer adaptive seal is designed to minimize paravalular leak. 
Currently 3 valve sizes are available; 23, 25 and 27 mm and are suitable for an aortic valve annulus in 
the range ≥19mm and ≤27mm. The 23mm valve is introduced through an 18F sheath and the 25 and 
27mm devices through a 20F sheath. The 18F sheath requires a vessel lumen of ≥6mm and the 20F 
requires a vessel lumen of ≥6.5mm. 
Patient selection 
10 patients unsuitable for trans-femoral access with any device used at our institution were selected 
for Lotus implantation if their left subclavian artery was of suitable calibre for Lotus sheath 
introduction, if there was absence of concentric calcification and if annular area assessed by CT was 
within the recommended range for the Lotus device (currently ≥314mm
2
 to ≤572mm
2
).  Assessment 
was made from the screening MDCT undertaken in all patients to assess access route. 
Subclavian access 
All procedures were performed under general anaesthesia with TOE monitoring. The left subclavian 
artery was exposed surgically and a  suitable access area was identified by inspection and palpation. 
Using a Seldinger technique the subclavian artery was punctured within a purse string suture and a 
5F 11cm sheath was introduced. Over a soft J-tipped 0.035” wire a 5F Judkins right catheter was 
positioned in the ascending aorta and the soft 0.035” wire exchanged for a 180cm Super Stiff 0.035” 
Amplatz wire. Over the stiff wire the 20F Lotus sheath was introduced with the distal tip placed in 
the ascending aorta under fluoroscopic guidance. The aortic valve was crossed and a 0.035” small or 
extra small Safari Wire (Boston Scientific, USA) was placed in the left ventricle.  Pre-dilatation was 
not performed in any patient. The Lotus valve was then introduced through the Lotus sheath with 
the catheter in an ‘S’ configuration and implanted with standard technique.  
Statistical methods 
The populations were described using median and interquartile range for continuous variables and 
percentage for categorical variables.  Statistical analysis was performed using STATA (College 
Station, USA).   
The study complies with the Declaration of Helsinki. The data were collected as part of a mandatory 
UK national cardiac audit and all patient identifiable fields were removed before analysis. The study 
complies with section 251 of the National Health Service Act 2006. Ethical approval was not required 
under research governance arrangements for analyses. 
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Results 
Baseline Demographics 
Baseline demographics are shown in table I.  
Patients who received transaortic/transapical TAVI had significantly higher Logistic Euroscore than 
the patients undergoing transfemoral TAVI (19 vs 14; p0.001). Logistic Euroscore was also 
numerically higher in the entire subclavian cohort compared with the transfemoral group, although 
this did not meet significance (22 vs 14; p=0.07). The transaortic/transapical and entire subclavian 
group more frequently had peripheral vascular disease than the transfemoral cohort (p<0.001). 
The 10 patients who underwent trans-subclavian TAVI were aged 75 years (69-83) with 60% being 
male. Compared with the trans-femoral group the cohort undergoing trans-subclavian TAVI with 
Lotus had more frequently undergone open heart surgery, had a greater frequency of peripheral 
vascular disease, diabetes and a higher BMI. Characteristics of the Lotus subclavian group were 
similar to the cohort who received trans-aortic or trans-apical TAVI. 
Procedural characteristics 
The majority of femoral TAVI cases were carried out under local anaesthetic whilst all trans-
subclavian cases and all transaortic/transapical cases were performed under general anaesthetic.  
The rates of post -dilatation and choice of TAVI valve used can also be seen in table II. 
Outcomes 
Procedural outcomes are shown in table III.  
Procedural success, defined as a successful attempt to implant a valve to the annulus, was high in 
the whole cohort with the valve implanted successfully in 99% of patients.  In the entire population 
rates of major complications including in-hospital death (4.7%), 30-day mortality (4.4%), peri-
procedural MI (1.6%), peri-procedural stroke (0.8%) and major access site complications (2.3%) were 
low.  The requirement for permanent pacing post TAVI and before discharge was 7.4%. 
All 10 patients undergoing trans-subclavian with Lotus required a 20F sheath for a 25 or 27mm valve. 
The sheath was successfully passed into the ascending aorta in 9 patients. In one patient, the tip of 
the sheath would not pass an area of calcification in the proximal subclavian artery, however, the 
delivery sheath, being of narrower diameter, successfully traversed the obstruction and the valve 
was deployed uneventfully. There was no haemodynamic instability or ECG evidence of ischaemia in 
any of the 4 patients with patent IMAs during the procedure following introduction of the sheath. 
Procedural success was achieved in all patients. Passage of the Lotus THV to the native aortic valve 
was uncomplicated in all patients. Due to the short distance from the access site to the native aortic 
valve and as the catheter was delivered in an ‘S’ configuration, the catheter naturally self-oriented 
and proved extremely easy to deliver. Post implant valve gradients were low and no patient required 
valvuloplasty post valve deployment. 4 of the 10 patients (40%) required a pacemaker due to heart 
block at the end of the procedure.  None of these patients had pre-existing conduction abnormalities 
such as right bundle branch block or first degree heart block on electrocardiogram.  There were no 
vascular complications or access site related problems in any of the 10 patients. 2 patients with 
morbid obesity (BMI 40 and 47) were extubated on ITU. The remaining 8 patients were extubated 
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immediately after TAVI in the catheter laboratory and then transferred directly to the coronary care 
unit.  Patients were able to mobilise quickly after the procedure. The median length of stay was 
significantly lower in the entire subclavian group compared with the transapical/transaortic group (3 
days vs 7 days, p<0.001).  Significantly more patients in the transaortic/transapical group (28%) 
required blood transfusions than the transfemoral group (9%) or subclavian group (6%).  No 
statistical difference was seen in the rate of blood transfusion between the subclavian and 
transfemoral groups. The transaortic/transapical group more frequently required dialysis than either 
the subclavian or transfemoral groups.  
Peak CRP and peak total CPK were both significantly higher in the transapical/transaortic cohort 
compared with the entire subclavian group. 67% of patients in the transapical/transaortic group 
required a chest drain compared with 0% in the subclavian group. 
 
Discussion 
Our study demonstrates that TAVI via the subclavian artery using the Lotus valve is feasible and safe 
with similar outcomes to those receiving transfemoral TAVI.  The valve was deployed successfully in 
all 10 patients with no major complications (death, peri-procedural stroke or MI, access site 
problems) until discharge.  This is the largest reported series of patients to have undergone TAVI via 
the subclavian artery with the Lotus valve.  It should be noted that in this cohort of patients there 
was a relatively high requirement for permanent pacing either during or immediately following the 
procedure (40% of patients).  A high rate of requirement for permanent pacing of 28.6% was also 
originally described with use of the valve from the femoral artery
22
.   None of the patients in our 
cohort of patients had moderate or severe paravalvular regurgitation. 
Patients who underwent subclavian TAVI had fewer deaths and TIA/stroke than the cohort of 
patients who underwent transapical or direct aortic TAVI.  Although both groups of patients required 
general anaesthesia and surgical cut down, transapical and direct aortic access are more invasive 
due to the need for a sternotomy or thoracotomy, and the requirement to open the pericardium. 
Transaortic/transapical access was associated with a higher need for blood transfusion than 
subclavian access and these patients also usually required a chest drain immediately following the 
procedure.  The greater invasiveness of transaortic/transapical access was reflected in the markedly 
higher peak CRP compared with the subclavian cohort. CRP is a marker of the systemic inflammatory 
response
23
 and a high CRP post cardiothoracic surgery is associated with a higher risk of major 
cardiovascular adverse events
24
. 
Further evidence of the more invasive nature of transapical/transaortic access was the observation 
that these patients experienced longer lengths of stay both in the intensive care unit and in hospital 
compared to patients who underwent subclavian TAVI.  This has important beneficial implications of 
subclavian access for both for patients, who enjoy a reduced hospital stay, and healthcare providers 
by reducing overall costs. 
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Study limitations 
The main limitation of our study is that the cohort of patients who underwent subclavian TAVI via 
the subclavian artery was relatively small at 16 patients.  A further limitation is that this is not a 
randomised study.  Finally, we do not yet have long term follow up data on the group of patients 
who had subclavian TAVI using Lotus. 
 
Conclusion 
In our cohort of patients, TAVI with the lotus valve using a trans-subclavian approach was safe and 
had outcomes comparable to TAVI via the transfemoral route.  Patients who underwent trans-
subclavian TAVI had significantly fewer complications and required a shorter hospital stay than those 
undergoing transaortic or direct apical procedures.  Our data are consistent with the growing body 
of evidence that suggests subclavian access is safer and less invasive than transaortic/transapical 
access and may be the preferred alternative access. 
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Table I - Baseline demographics of patients undergoing TAVI 
Variable Subclavian (all) 
(n= 16) 
Subclavian 
(Lotus)(n=10) 
 
Transapical and 
direct aortic 
(n=45) 
Femoral 
(n= 347) 
P value femoral 
vs transaortic/ 
transapical* 
P value femoral 
vs subclavian* 
P value 
subclavian vs 
transaortic/ 
transapical* 
Age, years 78 [72-84] 75 [69-83] 81 [75-85] 83 [78-86] 0.38 0.20 0.83 
Male sex 12 (75%) 6 (60%) 24 (53%) 190 (55%) 0.86 0.11 0.13 
Logistic Euroscore 19 [15-24] 22 [17-28] 21 [15-31] 14 [10-24] 0.001 0.07 0.77 
BMI 29.0 [26.4-
34.6] 
30.9 [26.8-36.2] 26.7 [23.5-29.4] 26.7 [24.1-
30.6] 
1.00 0.44 0.71 
Diabetes 6 (38%) 5 (50%) 12 (27%) 107 (31%) 0.57 0.57 0.41 
Creatinine 88 [80-115] 81 [80-89] 92 [77-131] 93 [77-125] 0.92 0.54 0.43 
Previous MI 7 (44%) 5 (50%) 15 (33%) 77 (22%) 0.10 0.05 0.46 
Previous PCI 6 (38%) 5 (50%) 8 (18%) 76 (22%) 0.53 0.15 0.11 
Previous cardiac 
surgery 
1 (6%) 1 (10%) 3 (7%) 23 (7%) 0.75 0.29 0.47 
Previous 
pacemaker 
5 (31%) 4 (40%) 10 (22%) 70 (20%) 0.99 0.95 0.95 
Current or Ex- 
Smoker 
15 (94%) 9 (90%) 34 (76%) 194 (56%) 0.01 0.003 0.12 
Atrial fibrillation 6 (38%) 3 (30%) 14 (31%) 87 (25%) 0.38 0.27 0.64 
Pulmonary 
hypertension 
(>60mmHg) 
0 (0%) 0 (0%) 31 (69%) 115 (33%) <0.001 0.005 <0.001 
Chronic lung 
disease 
9 (56%) 5 (50%) 14 (31%) 82 (24%) 0.27 0.003 0.08 
TIA/CVA 5 (31%) 4 (40%) 6 (13%) 63 (18%) 0.42 0.19 0.11 
Peripheral 
vascular disease 
13 (81%) 9 (90%) 25 (56%) 73 (21%) <0.001 <0.001 0.07 
AV peak gradient 74 [65-78] 74 [60-77] 78 [65-96] 71 [60-85] 0.11 0.59 0.22 
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*P-values based on Person chi
2
 comparing medians for continuous variables and chi
2
test for categorical variables. 
 
(mmHg) 
AV area (cm2) 0.7 [0.6-0.8] 0.8 [0.6-0.8] 0.6 [0.5-0.7] 0.6 [0.5-0.8] 0.008 0.79 0.10 
Aortic annulus 
(mm) 
25 [24-27] 24 [24-25] 23 [21-25] 24 [22-25] 0.26 0.09 0.16 
LV >50% 
LV 30-49% 
LV <30% 
12 (75%) 
2 (13%) 
2 (13%) 
7 (70%) 
1 (10%) 
2 (20%) 
10 (22%) 
30 (67%) 
5 (11%) 
202 (58%) 
102 (29%) 
43 (12%) 
<0.001 0.32 <0.001 
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Table II – Procedural characteristics 
 
 Subclavian (all) 
(n= 16) 
Subclavian 
(Lotus)(n=10) 
 
Transapical and 
direct aortic 
(n=45) 
Femoral 
(n= 347) 
P value femoral 
vs transaortic/ 
transapical* 
P value femoral 
vs subclavian* 
P value 
subclavian vs 
transaortic/ 
transapical* 
Local anaesthesia 0 (0%) 0 (0%) 0 (0%) 210 (61%)    
Post dilatation of 
the implanted 
valve 
3 (19%) 0 (0%) 2 (13%) 81 (29%) 0.16 0.40 0.63 
Lotus 10 10 1 22    
Sapien/S3/XT 2 0 44 323    
Evolute 
R/Corevalve 
4 0 0 2    
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Table III - Outcomes in patients undergoing TAVI 
 Subclavian 
(all) (n= 16) 
Subclavian 
(Lotus)(n= 10) 
 
Transapical and 
direct aortic (n= 
45) 
Femoral 
(n= 347) 
P value 
femoral vs 
transaortic/ 
transapical* 
P value 
femoral vs 
subclavian* 
P value 
subclavian 
vs 
transaortic/ 
transapical* 
Procedural 
success 
16 (100%) 10 (100%) 44 (98%) 343 (99%) 0.55 0.67 0.55 
In hospital death 0 (0%) 0 (0%) 5 (11%) 14 (4%) 0.04 0.41 0.16 
30 day mortality 0 (0%) 0 (0%) 5 (11%) 13 (4%) 0.03 0.43 0.16 
Stroke/TIA to 
discharge 
0 (0%) 0 (0%) 2 (4%) 1 (0.3%) 0.003 0.83 0.39 
Tamponade 0 (0%) 0 (0%) 1 (2%) 10 (3%) 0.80 0.49 0.55 
Periprocedural MI 0 (0%) 0 (0%) 1 (2%) 5 (1%) 0.69 0.63 0.55 
AR by echo 
(moderate or 
more) 
0 (0%) 0 (0%) 0 (0%) 4 (1%) 0.47 0.67 - 
Emergency valve 
in valve 
1 (6%) 0 (0%) 0 (0%) 2 (0.6%) 0.61 0.01 0.09 
Major access site 
complication 
0 (0%) 0 (0%) 2 (4%) 13 (4%) 0.82 0.43 0.39 
Permanent 
pacemaker during 
or post procedure 
6 (38%) 4 (40%) 2 (4%) 22 (6%) 0.62 <0.001 0.001 
New 
haemofiltration or 
dialysis 
0 (0%) 0 (0%) 5 (11%) 15 (4%) 0.05 0.40 0.16 
Blood transfusion 1 (6%) 0 (0%) 11 (28%) 28 (9%) <0.001 0.73 <0.001 
LOS (length of 
stay) 
3 [2-3] 3 [2-3] 7 [5-11] 3 [2-5] <0.001 0.19 <0.001 
LOS (in ICU) 0 [0-0] 0 [0-1] 2 [1-4] - - - 0.001 
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Peak CRP 57 [43-89] 53 [28-74] 197 [138-278] - - - <0.001 
Peak CK 167 [93-
202] 
150 [104-244] 270 [197-444] - - - 0.003 
Chest drain 0 (0%) 0 (0%) 30 (67%) - - - <0.001 
*P-values based on Person chi
2
 comparing medians for continuous variables and chi
2
 test for categorical variables. 
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